Pfizer and BioNTech announce vaccine candidate against COVID-19 achieved success in first interim analysis from Phase 3 study

Business & Industry News Channel
Sanofi and GSK intend to make available 200 million doses of their adjuvanted recombinant protein-based COVID-19 vaccine, if approved by regulatory authorities and subject to contract, to the COVAX Facility.
The foundation of Lumis Consult allows Lumis to expand its consulting business in a major strategic step. It reflects the increasing demand by biopharmaceutical companies for support in accelerating the clinical development of innovative drugs and medical devices.